<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02494973</url>
  </required_header>
  <id_info>
    <org_study_id>2014-005110-32</org_study_id>
    <secondary_id>2014/2187</secondary_id>
    <nct_id>NCT02494973</nct_id>
  </id_info>
  <brief_title>Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases</brief_title>
  <acronym>PACHA-01</acronym>
  <official_title>Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases - A Randomized Phase II/III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, no adjuvant study with hepatic arterial infusion in the adjuvant setting is&#xD;
      opened. Recently, the results of a phase II study (NCT00268463, NSABP-C-09) assessing the&#xD;
      potential benefit of systemic oxaliplatin and capecitabine alternating with HAI of FUDR,&#xD;
      after resection of CRLM have been reported.&#xD;
&#xD;
      The primary end point was 2-year survival. Fifty-five of 76 eligible patients were able to&#xD;
      initiate protocol-directed therapy and completed median of six cycles (range, one to six).&#xD;
      Three postoperative or treatment-related deaths were reported. Overall, 88% of evaluable&#xD;
      patients were alive at 2 years. With a median followup of 4.8 years, a total of 30 patients&#xD;
      have had disease recurrence, 11 involving the liver. Median disease-free survival was 32.7&#xD;
      months. In conclusion alternating HAI of FUDR and systemic capecitabine and oxaliplatin met&#xD;
      the prespecified end point of higher than 85% survival at 2 years and were clinically&#xD;
      tolerable.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2028</completion_date>
  <primary_completion_date type="Anticipated">May 2028</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>18-month hepatic RFS rate</measure>
    <time_frame>Assessed 18 months after inclusion</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>3-year RFS rate</measure>
    <time_frame>Assessed 3 years after inclusion</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Adjuvant systemic chemotherapy with mFOLFOX6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>started within 8 weeks after surgery for a maximal duration of 6 months and at least 3 months, every 14 days:&#xD;
Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,&#xD;
Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant HAI oxaliplatin and systemic LV5FU2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>started within 8 weeks after surgery for a maximal duration of 6 months and at least 3 months, and performed every 14 days:&#xD;
Oxaliplatin 85 mg/m² in 4-6 hours HAI day (D)1,&#xD;
Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours. In both arms, continuation of targeted therapy (if any) used in the preoperative treatment is allowed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin HAI</intervention_name>
    <description>Oxaliplatin 85 mg/m² in 2 hours HAI day (D)1,</description>
    <arm_group_label>Adjuvant HAI oxaliplatin and systemic LV5FU2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin IV</intervention_name>
    <description>Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,</description>
    <arm_group_label>Adjuvant systemic chemotherapy with mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX6</intervention_name>
    <description>Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.</description>
    <arm_group_label>Adjuvant systemic chemotherapy with mFOLFOX6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LV5FU2</intervention_name>
    <description>Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours.</description>
    <arm_group_label>Adjuvant HAI oxaliplatin and systemic LV5FU2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed metastatic colorectal adenocarcinoma,&#xD;
&#xD;
          2. Curative-intent resection (or ablation) R0 of at least 4 CRLM,&#xD;
&#xD;
          3. Preoperative oxaliplatin- and/or irinotecan-based chemotherapy (successively or&#xD;
             concomitantly) +/- non experimental biological therapy, e.g., anti-EGFR or&#xD;
             antiangiogenic antibody,&#xD;
&#xD;
          4. Confirmed radiological tumor control before surgery (i.e., objective response or&#xD;
             stable disease according to RECIST1.1 criteria),&#xD;
&#xD;
          5. WHO performance status of 0 or 1,&#xD;
&#xD;
          6. Age ≥ 18 years,&#xD;
&#xD;
          7. Adequate hematological function: absolute neutrophil count (ANC) &gt; 2 x 109/L;&#xD;
             platelets &gt; 100 x 10^^9/L, hemoglobin (Hb) &gt; 9 g/dL.&#xD;
&#xD;
          8. Adequate liver function: serum bilirubin &lt;/= 1.5 x ULN;&#xD;
&#xD;
          9. Aminotransferases levels &lt;/= 2.5 ULN (&lt;/= 5 ULN if liver metastases in place), and&#xD;
             alkaline phosphatase level ≤ 5 ULN&#xD;
&#xD;
         10. Creatinin clearance ≥ 30 ml/min&#xD;
&#xD;
         11. Informed consent signed by the patient or his/her legal representative.&#xD;
&#xD;
         12. Negative pregnancy test in women of childbearing potential within 14 days prior to&#xD;
             treatment initiation (premenopausal or less than 12 months of amenorrhea&#xD;
             post-menopause, and who have not undergone surgical sterilization). Both men and women&#xD;
             (of childbearing potential) who are sexually active must use adequate contraception,&#xD;
             during and for at least 6 months post-treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Extrahepatic metastatic disease (except ≤3 lung nodules (≤10 mm on chest CT scan)&#xD;
             deemed amenable to curative-intent resection/ablation),&#xD;
&#xD;
          2. Symptomatic primary tumor requiring urgent surgery, asymptomatic primary colorectal&#xD;
             tumor is not a non-inclusion criteria if its&#xD;
&#xD;
          3. Contraindication to fluoropyrimidines or oxaliplatin, as mentioned in the SMPC of&#xD;
             investigational medicinal products&#xD;
&#xD;
          4. Known dihydropyrimidine dehydrogenase (DPD) deficiency&#xD;
&#xD;
          5. Disease progression during, or early hepatic relapse (&lt; 6 months) after the end of,&#xD;
             oxaliplatin-based adjuvant chemotherapy following primary tumor resection&#xD;
&#xD;
          6. History of hepatic arterial infusion with any treatment (chemotherapy,&#xD;
             radioembolisation),&#xD;
&#xD;
          7. Peripheral neuropathy&gt; grade 1,&#xD;
&#xD;
          8. History of cancer within 5 years prior to entry into the trial other than adequately&#xD;
             treated basal-cell skin cancer or in situ carcinoma of the cervix&#xD;
&#xD;
          9. Concomitant administration of cimetidine&#xD;
&#xD;
         10. Concomitant medications/comorbidities that may prevent the patient from receiving&#xD;
             study treatments,&#xD;
&#xD;
         11. Patient already included in another clinical trial with an experimental molecule,&#xD;
&#xD;
         12. Pregnancy or lactation,&#xD;
&#xD;
         13. Patients deprived of liberty or under guardianship,&#xD;
&#xD;
         14. Patients unable to undergo medical monitoring test for geographical, social or&#xD;
             psychological reasons.&#xD;
&#xD;
         15. Patients must not have any uncontrolled concurrent illness including, but not limited&#xD;
             to, severe active or uncontrolled infection, symptomatic congestive heart failure,&#xD;
             unstable, angina pectoris, cardiac arrhythmia, uncontrolled diabetes mellitus or&#xD;
             psychiatric illness/social situations that would limit compliance with study&#xD;
             requirements resection is planned (REVERSE strategy authorized)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Diane Goéré, MD</last_name>
    <phone>0142115441</phone>
    <phone_ext>+33</phone_ext>
    <email>diane.goere@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean Pierre Pignon, MD</last_name>
    <phone>0142114565</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-pierre.pignon@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus Grand Paris</name>
      <address>
        <city>Villejuif</city>
        <state>Val De Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Goéré, MD</last_name>
      <phone>0142115441</phone>
      <phone_ext>+33</phone_ext>
      <email>diane.goéré@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Aurélie Abou Lovergne</last_name>
      <phone>0142113862</phone>
      <phone_ext>+33</phone_ext>
      <email>aurelie.aboulovergne@gustaveroussy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Diane Goéré, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 8, 2015</study_first_submitted>
  <study_first_submitted_qc>July 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2015</study_first_posted>
  <last_update_submitted>July 20, 2018</last_update_submitted>
  <last_update_submitted_qc>July 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

